Combined inhibitory receptor blockade therapy recruited enolase-active CD8+ TILs into tumours, whereas targeting individual checkpoint molecules did not significantly improve enolase activity in CD8+ T cells [126]. The gene discussed is CD8A; the disease is neoplasm.